Clinical trial · no report yet · Phase 2

LEANOX

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

NCT03255434 ↗
Active, not recruiting
Institut du Cancer de Montpellier - Val d'Aurelle
Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	10
Podcasts	1

The trial

ClinicalTrials.gov

Official title: LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Stage III Colon Cancer Patients Treated in Adjuvant Setting: Impact on Oxaliplatin-induced Sensitive Neurotoxicity. A Multicenter Phase II Randomized Trial (LEANOX)
Phase: Phase 2
Status: Active, not recruiting
Conditions: Stage III Colon Cancer
Interventions: Oxaliplatin; Oxaliplatin LBM
Arms: Folfox 4 · Active comparator
Folfox 4 LBM · Experimental
Enrollment: 160
Primary outcomes: Evaluation of neurotoxicity associated with Oxaliplatin
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Start: Nov 1, 2017
Primary completion: Jul 28, 2022
Results posted: No
Registry record: NCT03255434 · updated Feb 13, 2025

Publications

linked from the registry

Assenat E, Ben Abdelghani M, Gourgou S, Perrier H, Akouz FK, Desgrippes R, Galais MP, Janiszewski C, Mazard T, Rinaldi Y, Lepage C, Tetreau R, Senesse P. Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. J Clin Oncol. 2025 Aug 10;43(23):2616-2627. doi: 10.1200/JCO-24-02754. Epub 2025 Jun 20. PubMed 40540704